Skip to main content
SpringerLink
Log in

Chemoprevention

  • Chapter
  • First Online:
Management of Prostate Cancer

  • 1272 Accesses

Abstract

Prostate cancer (PCa) represents one of the most common cancers in male over 70 years of age in Europe. The incidence of clinical PCa varies widely between different geographical areas, being high in the USA and Northern Europe and low in Southeast Asia. But if one Japanese moves to the USA, the risk of PCa increases (Breslow et al. Int J Cancer 20:680, 1977). These results indicate there are exogenous factors that affect the risk of PCa, such as diet and environment. For its slow development, PCa is an ideal candidate for exogenous preventive measures. However, there is currently no strong evidence to suggest that dietary interventions can reduce the risk of PCa (EAU-ESTRO-SIOG guidelines on prostate cancer. Eur Assoc Urol, 2016). The aim of this chapter is to review the current scientific evidence and the most relevant epidemiological studies regarding the chemoprevention in PCa. However, the approach to study the role of chemopreventive agents lacks systemic process, and currently no dietary behavior factors are known to prevent the developing of PCa.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Breslow N, et al. Latent carcinoma of prostate at autopsy in seven areas, The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 1977;20:680.

    Article  CAS  PubMed  Google Scholar 

  2. Mottet N. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Eur Urol. 2016. http://dx.doi.org/ 10.1016/j.euro.2016.08.003 (Epub ahead of print).

  3. Kristal AR, et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. J Natl Cancer Inst. 2014;106(3):djt456.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Nicastro HL, Dunn BK. Selenium and prostate cancer prevention: insights from the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutrients. 2013;5:1122–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lippman SM, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers. The selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009;301(1):39–51.

    Article  CAS  PubMed  Google Scholar 

  6. Clark LC, et al. Nutritional Prevention of Cancer Study Group. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA. 1996;276(24):1957–63.

    Article  CAS  PubMed  Google Scholar 

  7. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330(15):1029–35.

    Article  Google Scholar 

  8. Klein EA, et al. Vitamin E and the risk of prostate cancer. The Selenium and Vitamin E Cancer Prevention trial (SELECT). JAMA. 2011;306(14):1549–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Antwi SO, et al. Dietary, supplement, and adipose tissue tocopherol levels in relation to prostate cancer aggressiveness among African and European Americans: the North Carolina-Louisiana Prostate Cancer Project (PCaP). Prostate. 2015;75:1419–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Vinceti M, et al.. Selenium for preventing cancer. Cochrane Database Syst Rev. 2014;(3):CD005195.

    Google Scholar 

  11. Schwarts GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990;10(5A):1307–11.

    Google Scholar 

  12. Schwarts GG. Vitamin D in blood and risk of prostate cancer: lessons from the Selenium and Vitamin E Cancer Prevention Trial and the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2014;23(8):1447–9.

    Article  Google Scholar 

  13. Pollack M, et al. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev. 1998;17:383–90.

    Article  Google Scholar 

  14. Margel D, et al. Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst. 2013;105:1123–31.

    Article  PubMed  Google Scholar 

  15. Kato H, et al. Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-lie growth factor 1 receptor. Biochem Biophys Res Commun. 2015;461:115–21.

    Article  CAS  PubMed  Google Scholar 

  16. Feng T, et al. Metformin use and risk of prostate cancer: results from the REDUCE study. Cancer Prev Res (Phila). 2015;8(11):1055–60.

    Article  CAS  Google Scholar 

  17. Wu GF, et al. Metformin therapy and prostate cancer risk: a meta-analysis of observational studies. Int J Clin Ext Med. 2015;8(8):13089–98.

    Google Scholar 

  18. Zhang ZJ, et al. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:707–10.

    Article  CAS  PubMed  Google Scholar 

  19. Rohrmann S, et al. Smoking and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 2013;108:708–14.

    Article  CAS  PubMed  Google Scholar 

  20. Mondul AM, et al. Association of serum α-tocopherol with sex steroid hormones and interactions with smoking: implications for prostate cancer risk. Cancer Causes Control. 2011;22:827–36.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Dixon RA, Pasinetti GM. Flavonoids and isoflavonoids: from plant biology to agriculture and neuroscience. Plant Physiol. 2010;154:453–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Boam T. Anti-androgenic effects of flavonols in prostate cancer. Ecancermedicalscience. 2015;9:585.

    PubMed  PubMed Central  Google Scholar 

  23. Kurahashi N, et al. Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: the Japan Public Health Center. J Clin Oncol. 2008;26(36):5923–9.

    Article  PubMed  Google Scholar 

  24. Kurahashi N, et al. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev. 2007;16(3):538–45.

    Article  CAS  PubMed  Google Scholar 

  25. Zhang HY, et al. Isoflavones and prostate cancer: a review of some critical issues. Chin Med J. 2016;129:341–7.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Van Poppel H, Tombal B. Chemoprevention of prostate cancer with nutrients and supplements. Cancer Manag Res. 2011;3:91–100.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Bettuzzi S, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006;66(2):1234–40.

    Article  CAS  PubMed  Google Scholar 

  28. Brausi S, et al. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol. 2008;54(2):472–3.

    Article  PubMed  Google Scholar 

  29. McLarty J, et al. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor vitro. Cancer Prev Res (Phila). 2009;2(7):673–82.

    Article  CAS  Google Scholar 

  30. Kurahashi N, et al. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol. 2008;167:71–7.

    Article  PubMed  Google Scholar 

  31. Ilic D, et al. Lycopene for the prevention of prostate cancer. Cochrane Database Syst Rev. 2011;(11):CD008007.

    Google Scholar 

  32. Chen P, et al. Lycopene and risk of prostate cancer. Medicine. 2015;94(33):1–14.

    Google Scholar 

  33. Key TJ, et al. Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. Am J Clin Nutr. 2015;102:1142–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Watson GW, et al. Phytochemicals from cruciferous vegetables epigenetics, and prostate cancer prevention. AAPS J. 2013;15(4):951–61.

    Article  CAS  Google Scholar 

  35. Thompson IM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:3. p 215–24.

    Google Scholar 

  36. Andriole GL, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:13. p 1192–202.

    Google Scholar 

  37. Roehrborn CG, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from CombAT study. Eur Urol. 2010;57:123–31.

    Article  PubMed  Google Scholar 

  38. Roehrborn CG, et al. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in Men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol. 2011;59:244–9.

    Article  CAS  PubMed  Google Scholar 

  39. Andriole GL, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology. 1998;52:195–202.

    Article  CAS  PubMed  Google Scholar 

  40. Fleshner NE, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:24–30.

    Article  Google Scholar 

  41. Ross AE, et al. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. BJU Int. 2012;110:651–7.

    Article  CAS  PubMed  Google Scholar 

  42. Wilt TJ, et al. 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int. 2010;106:1444–51.

    Article  CAS  PubMed  Google Scholar 

  43. Mahmud S, et al. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Database of Abstracts of Reviews of Effects 2015 Issue 2. Original article: Br J Cancer. 2004;90(1):93–99.

    Google Scholar 

  44. Veitonmäki T, et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial. Prostate. 2015;75:1394–402.

    Google Scholar 

  45. Vidal AC, et al. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res. 2015;21(4):756–62.

    Article  CAS  PubMed  Google Scholar 

  46. Liu Y, et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med. 2014;12:55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Zhijun W, et al. Nutraceuticals for prostate cancer chemoprevention: from molecular mechanism to clinical application. Expert Opin Investig Drugs. 2013;22(12):1613–36.

    Article  Google Scholar 

  48. Mandair D, et al. Prostate cancer and the influence of dietary factors and supplements: a systematic review. Nutr Metab. 2014;11:30.

    Article  Google Scholar 

  49. Wu K, et al. Associations between unprocessed red and processed meat, poultry, seafood and egg intake and the risk of prostate cancer: a pooled analysis of 15 prospective cohort studies. Int J Cancer. “Accepted article”. doi:10.1002/ijc.29973.

  50. Bylsma LC, Alexander DD. A review and meta-analysis of prospective studies of red and processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate cancer. Nutr J. 2015;14:125.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Melnik BC, et al. The impact of cow’s milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer. Nutr Metab. 2012;9:74.

    Article  CAS  Google Scholar 

  52. Song Y, et al. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr. 2013;143(2):189–96.

    Article  CAS  PubMed  Google Scholar 

  53. Lovegrove C, et al. Systematic review of prostate cancer risk and association with consumption of fish and fish-oils: analysis of 495,321 participants. Int J Clin Pract. 2015;69(1):87–105.

    Article  CAS  PubMed  Google Scholar 

  54. Joniau S, et al. Effect of nutritional supplement challenge in patients with isolated high-grade prostatic intraepithelial neoplasia. Urology. 2007;69:1101–6.

    Article  Google Scholar 

  55. Taneja SS, et al. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol. 2013;31:523–9.

    Article  CAS  PubMed  Google Scholar 

  56. Price D, et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol. 2006;176:965–70.

    Article  CAS  PubMed  Google Scholar 

  57. Marshall JR, et al. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res. 2011;4:1761–9.

    Article  CAS  Google Scholar 

  58. Fleshner NE, et al. Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination Vitamin-E, soy, and selenium. J Clin Oncol. 2011;29:2386–90.

    Article  CAS  PubMed  Google Scholar 

  59. Gontero P, et al. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or “chemopromotion”? Prostate. 2015;75:1177–86.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of University Urology, Città della Salute e della Scienza – Molinette, Turin, Italy

    Antonino Battaglia & Paolo Gontero

  2. Department of Development and Regeneration, University Hospitals Leuven, Urology, Leuven, Belgium

    Antonino Battaglia, Thomas Van de Broeck, Lisa Moris, Lorenzo Tosco, Wouter Everaerts, Maarten Albersen, Hendrik Van Poppel & Steven Joniau

  3. KU Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium

    Thomas Van de Broeck, Lisa Moris & Frank Claessens

  4. KU Leuven, Nuclear Medicine and Molecular Imaging, Leuven, Belgium

    Lorenzo Tosco

  5. Department of Oncology, University Hospitals Leuven, Radiation Oncology, Leuven, Belgium

    Gert De Meerleer

  6. Department of Urology, Lithuanian Health Science University, Eiveniu 2, 50009, Kaunas, Lithuania

    Daimantas Milonas

  7. Department of Urology, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Lithuania

    Daimantas Milonas

Authors
  1. Antonino Battaglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Van de Broeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lisa Moris
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lorenzo Tosco
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wouter Everaerts
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maarten Albersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Frank Claessens
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gert De Meerleer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hendrik Van Poppel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Paolo Gontero
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Daimantas Milonas
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Steven Joniau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Joniau .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Hôpital Albert Michallon, Grenoble, France

    Michel Bolla

  2. Department of Urology, University Hospitals Leuven, Leuven, Belgium

    Hendrik van Poppel

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Battaglia, A. et al. (2017). Chemoprevention. In: Bolla, M., van Poppel, H. (eds) Management of Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-42769-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42769-0_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42768-3

  • Online ISBN: 978-3-319-42769-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation